Procept Biorobotics Revenue Growth Rates (PRCT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Procept Biorobotics Corporation  (NASDAQ: PRCT)
 

PRCT's Revenue Growth by Quarter and Year

Procept Biorobotics's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PRCT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 94.50
1st Quarter March 82.95
FY 177.45

PRCTs Annual Revenue
Procept Biorobotics's Revenue in the fiscal year 2025 $ 307.23 millions
Procept Biorobotics's Revenue in the fiscal year 2024 $ 224.10 millions
Procept Biorobotics's Revenue in the fiscal year 2023 $ 136.05 millions
Procept Biorobotics's Revenue in the fiscal year 2022 $ 75.01 millions
Procept Biorobotics's Revenue in the fiscal year 2021 $ 34.47 millions




PRCT Revenue second quarter 2026 Y/Y Growth Comment
Procept Biorobotics Corporation reported Revenue increase of 20% year on year in the second quarter 2026, to $ 94.50 millions, this is lower than Procept Biorobotics Corporation's recent average Revenue rise of 82.27%.

Looking into second quarter 2026 results within Medical Equipment & Supplies industry 63 other companies have achieved higher Revenue growth. While Procept Biorobotics Corporation' s Revenue growth of 20% ranks overall at the positon no. 1037 in the second quarter 2026.


PRCT Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 9.53 % 59.54 % 83.64 %
3rd Quarter September - 43.34 % 66.07 % 71.35 %
2nd Quarter June 20 % 50.06 % 58.55 % 98.32 %
1st Quarter March 19.94 % 57.07 % 80.45 % 71.83 %
FY   - 37.1 % 64.72 % -

Financial Statements
Procept Biorobotics's second quarter 2026 Revenue $ 94.50 millions PRCT's Income Statement
Procept Biorobotics's second quarter 2025 Revenue $ 78.75 millions Quarterly PRCT's Income Statement


PRCT Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -8.07 % 20.31 % 25.24 %
3rd Quarter September - 5.41 % 10.35 % 5.35 %
2nd Quarter June 13.92 % 13.87 % 19.19 % 35.66 %
1st Quarter March 8.7 % -0.73 % 0.82 % 2.61 %
FY (Year on Year)   - 37.1 % 64.72 % -


Back to PRCT Growth rate Comparisons >> Back to PRCT Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #64
Healthcare Sector #207
Overall #1037

Revenue Y/Y Growth Statistics
High Average Low
311.39 % 82.27 % 9.53 %
(Dec 31 2022)   (Jun 30 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #64
Healthcare Sector #207
Overall #1037
Revenue Y/Y Growth Statistics
High Average Low
311.39 % 82.27 % 9.53 %
(Dec 31 2022)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Procept Biorobotics's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
166.26 % 20.89 % -8.06 %
(Dec 31 2020)  


PRCT's II. Quarter Q/Q Revenue Comment
Procept Biorobotics Corporation achieved in the II. Quarter 2026 below company average Revenue rise of 13.92% quarter on quarter, to $ 94.50 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 13.87% in the II. Quarter a year ago.

Within Medical Equipment & Supplies industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Procept Biorobotics's Revenue growth quarter on quarter, overall rank is 672.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #31
Healthcare Sector #116
Overall #672
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #31
Healthcare Sector #116
Overall #672
Revenue Q/Q Growth Statistics
High Average Low
166.26 % 20.89 % -8.06 %
(Dec 31 2020)  


PRCT's II. Quarter Q/Q Revenue Comment
Procept Biorobotics Corporation achieved in the II. Quarter 2026 below company average Revenue rise of 13.92% quarter on quarter, to $ 94.50 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 13.87% in the II. Quarter a year ago.

Within Medical Equipment & Supplies industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Procept Biorobotics's Revenue growth quarter on quarter, overall rank is 672.


Procept Biorobotics's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 336.76 $ 321.01 $ 307.23 $ 300.59 $ 275.49
Y / Y Revenue Growth (TTM) 22.24 % 28.8 % 37.09 % 51.74 % 57.37 %
Year on Year Revenue Growth Overall Ranking # 302 # 210 # 95 # 89 # 137
Seqeuential Revenue Change (TTM) 4.91 % 4.49 % 2.21 % 9.11 % 10.54 %
Seq. Revenue Growth (TTM) Overall Ranking # 1442 # 1132 # 687 # 650 # 929


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Procept Biorobotics's cumulative twelve months Revenue were $ 337 millions, company would post below average annual Revenue growth of 10.54% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Procept Biorobotics's Revenue growth from the 82.95% growth in Mar 31 2026.

In the Healthcare sector 81 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 210 to 302.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 93
Healthcare Sector # 82
Overall # 302

Revenue TTM Y/Y Growth Statistics
High Average Low
117.6 %
 74.3 %
22.24 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 93
Sector # 244
S&P 500 # 1442
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Procept Biorobotics's cumulative twelve months Revenue were $ 337 millions, company would post below average annual Revenue growth of 22.24% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Procept Biorobotics's Revenue growth from the 82.95% growth in Mar 31 2026.

In the Healthcare sector 81 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 210 to 302.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 93
Healthcare Sector # 82
Overall # 302

Revenue TTM Y/Y Growth Statistics
High Average Low
117.6 %
74.3 %
22.24 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 93
Sector # 244
S&P 500 # 1442




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PRCT's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Inspiremd Inc 34.88%$ 34.882 millions
The Oncology Institute Inc 34.62%$ 34.624 millions
Agenus Inc34.36%$ 34.358 millions
Biodesix Inc 34.18%$ 34.184 millions
Myomo Inc 33.82%$ 33.819 millions
Ligand Pharmaceuticals Incorporated33.73%$ 33.733 millions
Biocryst Pharmaceuticals Inc 33.61%$ 33.606 millions
Biofrontera Inc 32.92%$ 32.924 millions
Ironwood Pharmaceuticals inc 32.62%$ 32.617 millions
Cadre Holdings inc 32.56%$ 32.561 millions
Supernus Pharmaceuticals inc 32.40%$ 32.399 millions
Corcept Therapeutics Inc31.74%$ 31.743 millions
Establishment Labs Holdings Inc 31.73%$ 31.733 millions
Aclarion Inc 30.48%$ 30.483 millions
Harmony Biosciences Holdings inc 30.42%$ 30.421 millions
Personalis Inc 29.96%$ 29.960 millions
Beone Medicines Ltd 29.69%$ 29.693 millions
Capsovision Inc 29.60%$ 29.598 millions
Intuitive Surgical Inc 29.27%$ 29.272 millions
Xeris Biopharma Holdings Inc 28.74%$ 28.741 millions
Ultragenyx Pharmaceutical Inc 28.53%$ 28.532 millions
Innoviva Inc 28.39%$ 28.391 millions
Electrocore Inc 28.03%$ 28.031 millions
Lightwave Logic Inc 27.91%$ 27.909 millions
American Shared Hospital Services27.15%$ 27.149 millions
Protalix Biotherapeutics inc 27.07%$ 27.066 millions
Alkermes Plc 26.97%$ 26.968 millions
Lucid Diagnostics Inc 26.74%$ 26.741 millions
Lifestance Health Group Inc 26.08%$ 26.076 millions
Ani Pharmaceuticals Inc25.87%$ 25.866 millions


About Procept Biorobotics Revenue Growth Rates (PRCT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Procept Biorobotics Corp (CIK 1588978).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001588978-26-000030
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Procept Biorobotics Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.